Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PY159 +/- pembrolizumab in advanced solid tumors
NCT04682431Phase 1Terminated
- Sponsor
- ImageneBio
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of PY159 in solid tumor (advanced stage), gynecologic cancer, breast cancer and 5 more (4 arms), sponsored by ImageneBio. Primary endpoints: Incidence of Adverse Events at 36 months and Dose Limiting Toxicity at 21 days. Started Nov 2020; status: terminated.
02
Drugs
PY159
03
Conditions
solid tumor (advanced stage)gynecologic cancerbreast cancercolorectal cancer (CRC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04682431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682431.